Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study
Abstract Aims/Introduction The EMPA‐REG OUTCOME® trial demonstrated benefits of empagliflozin, a sodium‐glucose cotransporter‐2 inhibitor (SGLT2i), on cardiovascular, renal outcomes and all‐cause mortality in patients with type 2 diabetes and established cardiovascular disease. The EMPRISE study pro...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-03-01
|
| Series: | Journal of Diabetes Investigation |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/jdi.13959 |
| _version_ | 1797895075415457792 |
|---|---|
| author | Dae Jung Kim Wayne H‐H Sheu Wook‐Jin Chung Daisuke Yabe Kyoung Hwa Ha Masaomi Nangaku Elise Chia‐Hui Tan Koichi Node Atsutaka Yasui Weiyu Lei Sunwoo Lee Laura Saarelainen Anouk Deruaz‐Luyet Moe H Kyaw Yutaka Seino EMPRISE East Asia Study Group |
| author_facet | Dae Jung Kim Wayne H‐H Sheu Wook‐Jin Chung Daisuke Yabe Kyoung Hwa Ha Masaomi Nangaku Elise Chia‐Hui Tan Koichi Node Atsutaka Yasui Weiyu Lei Sunwoo Lee Laura Saarelainen Anouk Deruaz‐Luyet Moe H Kyaw Yutaka Seino EMPRISE East Asia Study Group |
| author_sort | Dae Jung Kim |
| collection | DOAJ |
| description | Abstract Aims/Introduction The EMPA‐REG OUTCOME® trial demonstrated benefits of empagliflozin, a sodium‐glucose cotransporter‐2 inhibitor (SGLT2i), on cardiovascular, renal outcomes and all‐cause mortality in patients with type 2 diabetes and established cardiovascular disease. The EMPRISE study program evaluates how these effects translate in a broad population of patients with type 2 diabetes in routine clinical care across countries. Materials and Methods The study included patients ≥18 years with type 2 diabetes initiating empagliflozin or any dipeptidyl peptidase‐4 inhibitors (DPP‐4i) from large administrative databases in Japan, South Korea, and Taiwan. Propensity score‐matched (1:1) ‘as‐treated’ analyses comparing the risk of cardiovascular outcomes and all‐cause mortality between empagliflozin and DPP‐4i use were performed in each country. Pooled hazard ratios (pHR) with 95% confidence intervals (CI) were computed using random effects meta‐analysis models comparing both empagliflozin and SGLT2i with DPP‐4i use, respectively. Intention‐to‐treat and subgroup analyses in patients with/without cardiovascular disease and in patients receiving 10 mg empagliflozin were performed. Results The study included 28,712 and 70,233 matched patient pairs for empagliflozin/DPP‐4i and SGLT2i/DPP‐4i analyses, respectively. The risk of composite outcomes including (i) hospitalization for heart failure (HHF) and all‐cause mortality was lower with empagliflozin (pHR 0.76, 95% CI 0.67–0.86) and SGLT2i (0.71, 0.65–0.77); (ii) combined myocardial infarction, stroke, and all‐cause mortality was also lower with empagliflozin (0.74, 0.61–0.88) and SGLT2i (0.69, 0.60–0.78) compared to DPP‐4i. The intention‐to‐treat and three subgroup analyses were consistent with results of the main analyses. Conclusions The results suggest that both empagliflozin and SGLT2i compared with DPP‐4i are associated with a lower risk of cardiovascular events and all‐cause mortality in routine clinical care in East Asia. |
| first_indexed | 2024-04-10T07:20:37Z |
| format | Article |
| id | doaj.art-4fadce44738c43919f7eaceb3654a8a9 |
| institution | Directory Open Access Journal |
| issn | 2040-1116 2040-1124 |
| language | English |
| last_indexed | 2024-04-10T07:20:37Z |
| publishDate | 2023-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Investigation |
| spelling | doaj.art-4fadce44738c43919f7eaceb3654a8a92023-02-24T12:37:44ZengWileyJournal of Diabetes Investigation2040-11162040-11242023-03-0114341742810.1111/jdi.13959Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE studyDae Jung Kim0Wayne H‐H Sheu1Wook‐Jin Chung2Daisuke Yabe3Kyoung Hwa Ha4Masaomi Nangaku5Elise Chia‐Hui Tan6Koichi Node7Atsutaka Yasui8Weiyu Lei9Sunwoo Lee10Laura Saarelainen11Anouk Deruaz‐Luyet12Moe H Kyaw13Yutaka Seino14EMPRISE East Asia Study GroupDepartment of Endocrinology and Metabolism Ajou University School of Medicine Suwon South KoreaDivision of Endocrinology and Metabolism Taipei Veterans General Hospital Taipei TaiwanDepartment of Cardiovascular Medicine Gachon University Gil Medical Center Incheon South KoreaKansai Electric Power Medical Research Institute Kobe JapanDepartment of Endocrinology and Metabolism Ajou University School of Medicine Suwon South KoreaDivision of Nephrology and Endocrinology The University of Tokyo Tokyo JapanNational Research Institute of Chinese Medicine, Ministry of Health and Welfare Taipei TaiwanDepartment of Cardiovascular Medicine Saga University Saga JapanNippon Boehringer Ingelheim Co. Ltd Tokyo JapanBoehringer Ingelheim Taiwan Ltd Taipei TaiwanBoehringer Ingelheim Korea Ltd Seoul South KoreaIQVIA Espoo FinlandBoehringer Ingelheim International GmbH Ingelheim GermanyBoehringer Ingelheim Pharmaceuticals, Inc. Ridgefield Connecticut USAKansai Electric Power Medical Research Institute Kobe JapanAbstract Aims/Introduction The EMPA‐REG OUTCOME® trial demonstrated benefits of empagliflozin, a sodium‐glucose cotransporter‐2 inhibitor (SGLT2i), on cardiovascular, renal outcomes and all‐cause mortality in patients with type 2 diabetes and established cardiovascular disease. The EMPRISE study program evaluates how these effects translate in a broad population of patients with type 2 diabetes in routine clinical care across countries. Materials and Methods The study included patients ≥18 years with type 2 diabetes initiating empagliflozin or any dipeptidyl peptidase‐4 inhibitors (DPP‐4i) from large administrative databases in Japan, South Korea, and Taiwan. Propensity score‐matched (1:1) ‘as‐treated’ analyses comparing the risk of cardiovascular outcomes and all‐cause mortality between empagliflozin and DPP‐4i use were performed in each country. Pooled hazard ratios (pHR) with 95% confidence intervals (CI) were computed using random effects meta‐analysis models comparing both empagliflozin and SGLT2i with DPP‐4i use, respectively. Intention‐to‐treat and subgroup analyses in patients with/without cardiovascular disease and in patients receiving 10 mg empagliflozin were performed. Results The study included 28,712 and 70,233 matched patient pairs for empagliflozin/DPP‐4i and SGLT2i/DPP‐4i analyses, respectively. The risk of composite outcomes including (i) hospitalization for heart failure (HHF) and all‐cause mortality was lower with empagliflozin (pHR 0.76, 95% CI 0.67–0.86) and SGLT2i (0.71, 0.65–0.77); (ii) combined myocardial infarction, stroke, and all‐cause mortality was also lower with empagliflozin (0.74, 0.61–0.88) and SGLT2i (0.69, 0.60–0.78) compared to DPP‐4i. The intention‐to‐treat and three subgroup analyses were consistent with results of the main analyses. Conclusions The results suggest that both empagliflozin and SGLT2i compared with DPP‐4i are associated with a lower risk of cardiovascular events and all‐cause mortality in routine clinical care in East Asia.https://doi.org/10.1111/jdi.13959Cardiovascular diseasesObservational studySodium‐glucose cotransporter 2 inhibitors |
| spellingShingle | Dae Jung Kim Wayne H‐H Sheu Wook‐Jin Chung Daisuke Yabe Kyoung Hwa Ha Masaomi Nangaku Elise Chia‐Hui Tan Koichi Node Atsutaka Yasui Weiyu Lei Sunwoo Lee Laura Saarelainen Anouk Deruaz‐Luyet Moe H Kyaw Yutaka Seino EMPRISE East Asia Study Group Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study Journal of Diabetes Investigation Cardiovascular diseases Observational study Sodium‐glucose cotransporter 2 inhibitors |
| title | Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study |
| title_full | Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study |
| title_fullStr | Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study |
| title_full_unstemmed | Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study |
| title_short | Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study |
| title_sort | empagliflozin is associated with lower risk of cardiovascular events and all cause mortality in routine care in east asia results from the emprise study |
| topic | Cardiovascular diseases Observational study Sodium‐glucose cotransporter 2 inhibitors |
| url | https://doi.org/10.1111/jdi.13959 |
| work_keys_str_mv | AT daejungkim empagliflozinisassociatedwithlowerriskofcardiovasculareventsandallcausemortalityinroutinecareineastasiaresultsfromtheemprisestudy AT waynehhsheu empagliflozinisassociatedwithlowerriskofcardiovasculareventsandallcausemortalityinroutinecareineastasiaresultsfromtheemprisestudy AT wookjinchung empagliflozinisassociatedwithlowerriskofcardiovasculareventsandallcausemortalityinroutinecareineastasiaresultsfromtheemprisestudy AT daisukeyabe empagliflozinisassociatedwithlowerriskofcardiovasculareventsandallcausemortalityinroutinecareineastasiaresultsfromtheemprisestudy AT kyounghwaha empagliflozinisassociatedwithlowerriskofcardiovasculareventsandallcausemortalityinroutinecareineastasiaresultsfromtheemprisestudy AT masaominangaku empagliflozinisassociatedwithlowerriskofcardiovasculareventsandallcausemortalityinroutinecareineastasiaresultsfromtheemprisestudy AT elisechiahuitan empagliflozinisassociatedwithlowerriskofcardiovasculareventsandallcausemortalityinroutinecareineastasiaresultsfromtheemprisestudy AT koichinode empagliflozinisassociatedwithlowerriskofcardiovasculareventsandallcausemortalityinroutinecareineastasiaresultsfromtheemprisestudy AT atsutakayasui empagliflozinisassociatedwithlowerriskofcardiovasculareventsandallcausemortalityinroutinecareineastasiaresultsfromtheemprisestudy AT weiyulei empagliflozinisassociatedwithlowerriskofcardiovasculareventsandallcausemortalityinroutinecareineastasiaresultsfromtheemprisestudy AT sunwoolee empagliflozinisassociatedwithlowerriskofcardiovasculareventsandallcausemortalityinroutinecareineastasiaresultsfromtheemprisestudy AT laurasaarelainen empagliflozinisassociatedwithlowerriskofcardiovasculareventsandallcausemortalityinroutinecareineastasiaresultsfromtheemprisestudy AT anoukderuazluyet empagliflozinisassociatedwithlowerriskofcardiovasculareventsandallcausemortalityinroutinecareineastasiaresultsfromtheemprisestudy AT moehkyaw empagliflozinisassociatedwithlowerriskofcardiovasculareventsandallcausemortalityinroutinecareineastasiaresultsfromtheemprisestudy AT yutakaseino empagliflozinisassociatedwithlowerriskofcardiovasculareventsandallcausemortalityinroutinecareineastasiaresultsfromtheemprisestudy AT empriseeastasiastudygroup empagliflozinisassociatedwithlowerriskofcardiovasculareventsandallcausemortalityinroutinecareineastasiaresultsfromtheemprisestudy |